These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 18841189)
1. Kava hepatotoxicity: a European view. Teschke R; Schwarzenboeck A; Akinci A N Z Med J; 2008 Oct; 121(1283):90-8. PubMed ID: 18841189 [TBL] [Abstract][Full Text] [Related]
6. Kava hepatotoxicity solution: A six-point plan for new kava standardization. Teschke R; Sarris J; Lebot V Phytomedicine; 2011 Jan; 18(2-3):96-103. PubMed ID: 21112196 [TBL] [Abstract][Full Text] [Related]
7. Kava extracts: safety and risks including rare hepatotoxicity. Teschke R; Gaus W; Loew D Phytomedicine; 2003; 10(5):440-6. PubMed ID: 12834011 [TBL] [Abstract][Full Text] [Related]
8. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. Teschke R; Fuchs J; Bahre R; Genthner A; Wolff A J Clin Pharm Ther; 2010 Oct; 35(5):545-63. PubMed ID: 20831679 [TBL] [Abstract][Full Text] [Related]
9. Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Teschke R; Qiu SX; Lebot V Dig Liver Dis; 2011 Sep; 43(9):676-81. PubMed ID: 21377431 [TBL] [Abstract][Full Text] [Related]
10. [Kava, kavapyrones and toxic liver injury]. Teschke R Z Gastroenterol; 2003 May; 41(5):395-404. PubMed ID: 12772052 [TBL] [Abstract][Full Text] [Related]
11. Risk of kava hepatotoxicity and the FDA consumer advisory. Teschke R; Schulze J JAMA; 2010 Nov; 304(19):2174-5. PubMed ID: 21081732 [No Abstract] [Full Text] [Related]
12. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate? Teschke R; Wolff A Regul Toxicol Pharmacol; 2011 Feb; 59(1):1-7. PubMed ID: 20854865 [TBL] [Abstract][Full Text] [Related]
13. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Russmann S; Barguil Y; Cabalion P; Kritsanida M; Duhet D; Lauterburg BH Eur J Gastroenterol Hepatol; 2003 Sep; 15(9):1033-6. PubMed ID: 12923378 [TBL] [Abstract][Full Text] [Related]
14. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence. Teschke R; Qiu SX; Xuan TD; Lebot V Phytother Res; 2011 Sep; 25(9):1263-74. PubMed ID: 21442674 [TBL] [Abstract][Full Text] [Related]
15. Kava hepatotoxicity: regulatory data selection and causality assessment. Teschke R; Wolff A Dig Liver Dis; 2009 Dec; 41(12):891-901. PubMed ID: 19477698 [TBL] [Abstract][Full Text] [Related]
16. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Teschke R; Sarris J; Schweitzer I Br J Clin Pharmacol; 2012 Feb; 73(2):170-4. PubMed ID: 21801196 [TBL] [Abstract][Full Text] [Related]
17. Kava update: a European perspective. Ernst E N Z Med J; 2004 Nov; 117(1205):U1143. PubMed ID: 15570327 [No Abstract] [Full Text] [Related]
18. Relevant hepatotoxic effects of kava still need to be proven. A statement of the Society for Medicinal Plant Research. Society for Medicinal Plant Research Planta Med; 2003 Nov; 69(11):971-2. PubMed ID: 14735431 [No Abstract] [Full Text] [Related]
19. Hepatic toxicity possibly associated with kava-containing products--United States, Germany, and Switzerland, 1999-2002. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(47):1065-7. PubMed ID: 12500906 [TBL] [Abstract][Full Text] [Related]